Severe Hypercalcemia in a Patient with Chronic Lymphocytic Leukemia following Treatment Disruption

慢性淋巴细胞白血病患者治疗中断后出现严重高钙血症

阅读:1

Abstract

INTRODUCTION: Hypercalcemia is a common paraneoplastic syndrome rarely seen in chronic lymphocytic leukemia (CLL). When it occurs, it often signals disease progression or Richter transformation. Disruption of cancer care in conflict zones may contribute to worsening clinical outcomes. CASE PRESENTATION: We report a 63-year-old Arab female with a 3-year history of CLL, previously treated with chlorambucil and rituximab, who developed severe hypercalcemia (total calcium 19.9 mg/dL) after an 8-month interruption of chemotherapy due to transportation barriers amid regional conflict. She presented with confusion, weakness, polyuria, and polydipsia. Laboratory evaluation showed suppressed parathyroid hormone, normal vitamin D, renal impairment, and no evidence of lytic bone lesions. Treatment with intravenous fluids, calcitonin, and zoledronic acid effectively lowered calcium levels. Despite reinitiation of chemotherapy, she later developed fatal febrile neutropenia and septic shock. CONCLUSION: This case highlights a rare but serious complication of CLL and underscores the detrimental impact of healthcare disruption on disease progression and outcomes. Clinicians should maintain vigilance for hypercalcemia in hematologic malignancies, even during remission, and prioritize continuity of care in vulnerable populations.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。